# Intensity Therapeutics, Inc.: overview INTS · Nasdaq · CIK 1567264 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ints.md) · [Financials](/companies/ints/financials.md) · [Filings](/companies/ints/filings.md) · [Insiders](/companies/ints/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.25)](/filings/0001567264-25-000103.md) | not reported | [(5.51)](/filings/0001567264-26-000046.md) | [(3.36)](/filings/0001567264-26-000059.md) | [(0.06)](/filings/0001567264-25-000103.md) | not reported | [(0.96)](/filings/0001567264-26-000046.md) | [(1.11)](/filings/0001567264-26-000059.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.22)](/filings/0001628280-24-011207.md) | [(1.38)](/filings/0001567264-25-000010.md) | [(29.24)](/filings/0001567264-26-000024.md) | [(8.56)](/filings/0001567264-26-000024.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ints/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [KMT WEALTH MANAGEMENT, LLC](/funds/2058235.md) | 2026-06-30 | $2.0m | 496,493 | | New +496,493 | | [Kingsbury Capital Investment Advisors LLC](/funds/1927315.md) | 2026-06-30 | $2.0m | 496,493 | | Not compared | | [Rothschild Wealth LLC](/funds/1811345.md) | 2026-06-30 | $109.6k | 26,723 | | Added +3,429 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $108.9k | 26,569 | | Added +9,728 | | [SAPIENT CAPITAL LLC](/funds/1998653.md) | 2026-06-30 | $106.6k | 26,006 | | Unchanged | | [NANO CAP NEW MILLENNIUM GROWTH FUND L P](/funds/1277890.md) | 2026-06-30 | $102.5k | 25,000 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $93.4k | 22,787 | | Reduced −3,232 | | [Mesirow Financial Investment Management, Inc.](/funds/1469475.md) | 2026-06-30 | $57.9k | 14,118 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $37.4k | 9,121 | | Unchanged | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $8.1k | 1,984 | | Added +1,917 | ## Recent filings [All 244 filings](/companies/ints/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 07:40 ET | [8-K](/filings/0001567264-26-000061.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001567264-26-000061 | | 2026-08-11 | 07:17 ET | [10-Q](/filings/0001567264-26-000059.md) | Quarterly report, period 2026-06-30 | 0001567264-26-000059 | | 2026-06-16 | 16:15 ET | [8-K](/filings/0001567264-26-000049.md) | 5.07 Shareholder vote results | 0001567264-26-000049 | | 2026-05-07 | 16:10 ET | [8-K](/filings/0001567264-26-000047.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001567264-26-000047 | | 2026-05-07 | 16:01 ET | [10-Q](/filings/0001567264-26-000046.md) | Quarterly report, period 2026-03-31 | 0001567264-26-000046 | | 2026-04-30 | 16:06 ET | [DEF 14A](/filings/0001567264-26-000035.md) | Proxy statement, period 2026-04-30 | 0001567264-26-000035 | | 2026-03-27 | 16:13 ET | [8-K](/filings/0001567264-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001567264-26-000025 | | 2026-03-27 | 16:01 ET | [10-K](/filings/0001567264-26-000024.md) | Annual report, period 2025-12-31 | 0001567264-26-000024 | | 2026-03-23 | 16:02 ET | [8-K](/filings/0001567264-26-000021.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001567264-26-000021 | | 2026-03-06 | 08:04 ET | [8-K](/filings/0001567264-26-000014.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001567264-26-000014 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001567264-26-000024.md), filed Mar 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1567264 - Tickers: INTS - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.